Antimicrobial susceptibility of Proteus mirabilis urinary tract isolates from 1999 to 2005 at Nîmes university hospital;Profils de résistance des souches urinaires de Proteus mirabilis de 1999 à 2005 au CHU de Nîmes

Pathologie Biologie

Volumn 54, Issue 8-9 SPEC.ISS., 2006, Pages 456-461

  Mahamat, A ^a,b   Lavigne, J P ^a,b   Bouziges, N ^a,b   Daures J P ^a,b   Sotto, A ^b  

^a DEPARTMENT OF NEUROLOGY   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

lactamase; Colonisation; ESBL; Infection; IRT; Proteus mirabilis; Resistance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAMASE; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; NALIDIXIC ACID; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; PIPERACILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; ANTIINFECTIVE AGENT; PENICILLIN DERIVATIVE;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; DRUG SENSITIVITY; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEUS MIRABILIS; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL; URINARY TRACT INFECTION; ANTIBIOTIC RESISTANCE; DRUG EFFECT; FRANCE; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; SENSITIVITY AND SPECIFICITY;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLINS; PROTEUS MIRABILIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; URINARY TRACT INFECTIONS;

EID: 33751056154     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2006.07.015     Document Type: Article

References (21)

1. Bonnet R., De Champs C., Sirot D., Chanal C., Labia R., and Sirot J. Diversity of TEM mutants in Proteus mirabilis. Antimicrob. Agents Chemother. 43 (1999) 2671-2677
2. Bouza E., San Juan R., Munoz P., Voss A., and Kluytmans J. European perspective on nosocomial urinary tract infections II. Report on incidence, clinical characteristics and outcome (ESGNI-004 study). European Study Group on Nosocomial Infection. Clin. Microbiol. Infect. 7 (2001) 532-542
3. Bret L., Chanal C., Sirot D., Labia R., and Sirot J. Characterization of an inhibitor-resistant enzyme IRT-2 derived from TEM-2 betalactamase produced by Proteus mirabilis strains. J. Antimicrob. Chemother. 38 (1996) 183-191
4. Cavallo J.D., and Péan Y.P.W. Facteurs influant sur la fréquence et sur le niveau de sensibilité aux antibiotiques des souches d'Escherichia coli et Proteus mirabilis isolées au cours des infections urinaires chez les patients ambulatoires : Observatoire national de l'épidémiologie de la résistance des bactéries aux antibiotiques (ONERBA). Med. Mal. Infect. 30 (2000) 714-720
5. Chanal C., Bonnet R., De Champs C., Sirot D., Labia R., and Sirot J. Prevalence of betalactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital. Antimicrob. Agents Chemother. 44 (2000) 1930-1935
6. Chanal C., Sirot D., Romaszko J.P., Bret L., and Sirot J. Survey of prevalence of extended spectrum betalactamases among enterobacteriaceae. J. Antimicrob. Chemother. 38 (1996) 127-132
7. de Champs C., Bonnet R., Sirot D., Chanal C., and Sirot J. Clinical relevance of Proteus mirabilis in hospital patients: a two-year survey. J. Antimicrob. Chemother. 45 (2000) 537-539
8. Delarbre J.M., Dubouix A., and Robert J. Antibiotic resistance: from the results of ONERBA's networks to good antibiotic use. Med. Mal. Infect. 35 Suppl 2 (2005) S108-S111
9. Farmer III J. Enterobacteriaceae: introduction and identification. In: Murray E.P.R., Pfaller M.A., Tenover F.C., and Yolken R.H. (Eds). Manual of clinical microbiology (1999), American Society for Microbiology Press, Washington, D.C 442-458
10. Hernandez J.R., Martinez-Martinez L., Pascual A., Suarez A.I., and Perea E.J. Trends in the susceptibilities of Proteus mirabilis isolates to quinolones. J. Antimicrob. Chemother. 45 (2000) 407-408
11. Luzzaro F., Perilli M., Amicosante G., Lombardi G., Belloni R., Zollo A., et al. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of [beta]-lactam/[beta]-lactamase inhibitor combinations. Int. J. Antimicrob. Agents 17 (2001) 131-135
12. Mariotte S., Nordmann P., and Nicolas M.H. Extended-spectrum betalactamase in Proteus mirabilis. J. Antimicrob. Chemother. 33 (1994) 925-935
13. Mathai D., Jones R.N., and Pfaller M.A. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalised patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn. Microbiol. Infect. Dis. 40 (2001) 129-136
14. Nagano N., Shibata N., Saitou Y., Nagano Y., and Arakawa Y. Nosocomial outbreak of infections by Proteus mirabilis that produces extended-spectrum CTX-M-2 type betalactamase. J. Clin. Microbiol. 41 (2003) 5530-5536
15. Pagani L., Migliavacca R., Pallecchi L., Matti C., Giacobone E., Amicosante G., et al. Emerging extended-spectrum betalactamases in Proteus mirabilis. J. Clin. Microbiol. 40 (2002) 1549-1552
16. Romaszko J.P., Bret L., Henquell C., Sirot D., Chanal C., and Sirot J. Detection of betalactamases resistant to inhibitors (IRT) by the disk diffusion method. Pathol. Biol. (Paris) 43 (1995) 306-309
17. Saurina G., Quale J.M., Manikal V.M., Oydna E., and Landman D. Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns. J. Antimicrob. Chemother. 45 (2000) 895-898
18. SFM. Communiqué du comité de l'antibiogramme de la Société française de microbiologie (2006)
19. Sirot J. Detection of extended-spectrum plasmid-mediated betalactamases by disk diffusion. Clin. Microbiol. Infect. 2 Suppl 1 (1996) S35-S39
20. Soussy C.J., Carret G., Cavallo J.D., Chardon H., Chidiac C., Choutet P., et al. Antibiogram Committee of the French Microbiology Society. Report 2000-2001. Pathol. Biol. (Paris) 48 (2000) 832-871
21. Yong D., Lim Y.S., Roh K.H., Choi Y.S., Park D.Y., Yum J.H., et al. The first detection of CTX-M-14 extended-spectrum betalactamase among diverse betalactamase producing Proteus mirabilis clinical isolates. Diagn. Microbiol. Infect. Dis 54 3 (2006) 237-239